Global Viral Vectors and Plasmid DNA 2021-2030 - Surge in Demand due to Increasing Number of COVID-19 Cases

Dublin, IRELAND


Dublin, Jan. 19, 2022 (GLOBE NEWSWIRE) -- The "Viral Vectors and Plasmid DNA Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

The global viral vectors & plasmid DNA market is expected to grow from $0.55 billion in 2020 to $0.64 billion in 2021 at a compound annual growth rate (CAGR) of 16.4%. The growth is mainly due to the outbreak of COVID-19 and requires targeted delivery of the drug to treat affected patients. The number of cases has been increasing resulting in a surge in demand for viral vectors & plasmid DNA.

The market is expected to reach $1.34 billion in 2025 at a CAGR of 20%.

The viral vectors & plasmid DNA market consists of sales of viral vectors & plasmid DNA and related services. The viral vectors & plasmid DNA are used for the delivery of cellular therapies, like gene therapy and immunotherapy, and also for treating some viral infections. The viral vectors & plasmid DNA are used for formulation development in research and development labs. The viral vectors are genetically engineered viruses carrying viral RNA or DNA that is non-infectious but still contain viral promoters and transgene. The plasmid DNA is a double-stranded extrachromosomal and circular DNA sequence that is capable of replication using the host cell's replication system.

The viral vectors & plasmid DNA market covered in this report is segmented by product into plasmid DNA, viral vectors and by applications into gene and cancer therapies, viral infections, immunotherapy, formulation development, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The unaffordable cost of gene therapies is a major challenge in the viral vectors & plasmid DNA market. The prices of gene therapies range between $0.2 million to $2.1 million. For instance, Gilead company's Yescarta is a gene therapy that costs around $0.3 million and Bluebird Bio's Letiglobin is another gene therapy costing around $2.1 million. The high price is due to various factors like government regulations, production costs, and so on. Therefore, the unaffordable cost of gene therapies is limiting the viral vector & plasmid DNA market growth.

In January 2020, Cognate Bioservices Inc, a US-based company skilled in cell and cell-mediated gene therapy products, acquired Cobra Biologics, specialized in providing manufacturing services for plasmid DNA and viral vector, for an undisclosed amount. The acquisition is expected to create a platform for the life cycle management of cell and gene therapy products. Cobra biologics is well established in the development and manufacture of a variety of viral vectors and DNA. The combined Cognate and Cobra expertise is expected to push both the businesses to a better position to respond to current and future market demand.

The rise in the global incidence of cancer is driving the viral vector & plasmid DNA market. According to American cancer society 2020, an estimated 1.8 million new cancer cases are diagnosed and 606,520 cancer deaths in the United States. The rise in the global incidence of cancer has boosted the demand for the viral vectors and plasmid DNA market.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Key Topics Covered:

1. Executive Summary

2. Viral Vectors & Plasmid DNA Market Characteristics

3. Viral Vectors & Plasmid DNA Market Trends and Strategies

4. Impact Of COVID-19 On Viral Vectors & Plasmid DNA

5. Viral Vectors & Plasmid DNA Market Size and Growth
5.1. Global Viral Vectors & Plasmid DNA Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of the Market
5.1.2. Restraints On the Market
5.2. Global Viral Vectors & Plasmid DNA Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of the Market
5.2.2. Restraints On the Market

6. Viral Vectors & Plasmid DNA Market Segmentation
6.1. Global Viral Vectors & Plasmid DNA Market, Segmentation by Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Plasmid DNA
  • Viral Vectors

6.2. Global Viral Vectors & Plasmid DNA Market, Segmentation by Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Gene and Cancer therapies
  • Viral Infections
  • Immunotherapy
  • Formulation Development
  • Others

6.3. Global Viral Vectors & Plasmid DNA Market, Segmentation by Disease, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Infectious Diseases
  • Genetic Disorders
  • Cancer
  • Others

6.4. Global Viral Vectors & Plasmid DNA Market, Segmentation by End User, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Research Institutes
  • Biopharmaceutical and Pharmaceutical Companies

7. Viral Vectors & Plasmid DNA Market Regional and Country Analysis
7.1. Global Viral Vectors & Plasmid DNA Market, Split by Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Viral Vectors & Plasmid DNA Market, Split by Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion


Companies Mentioned

  • 4D Molecular Therapeutics
  • ALDEVRON
  • BioReliance
  • Biovian
  • Brammer Bio
  • Cell and Gene Therapy Catapult
  • Cobra Biologics and Pharmaceutical Services
  • FinVector Vision Therapies
  • FUJIFILM Diosynth Biotechnologies
  • Genzyme Corporation
  • Lonza
  • MassBiologics
  • MolMed
  • Novasep
  • Oxford BioMedica
  • Oxford Gene Technology
  • Plasmid Factory
  • Renova Therapeutics
  • Richter-Helm
  • Sanofi
  • Shenzhen SiBiono GeneTech Co.
  • SIRION Biotech GmbH
  • Spark Therapeutics
  • Thermo Fisher Scientific
  • UniQure
  • VGXI
  • Vigene Biosciences Inc.
  • VIROVEK
  • ??n?k? ??r??r?t??n
  • ??l?n NV


For more information about this report visit https://www.researchandmarkets.com/r/al15o6

 

Coordonnées